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Human immunodeficiency virus type 1 (HIV-1) isolates vary in their ability to infect macrophages. Previous
experiments have mapped viral determinants of macrophage infectivity to the V3 hypervariable region of the
HIV-1 envelope glycoprotein. In our earlier studies, V1 and V2 sequences of HIV-1 were also shown to alter the
ability of virus to spread in macrophage cultures, whereas no effect was seen in lymphocyte cultures. In the
present study, determinants that allowed certain HIV-1 clones to infect and spread in macrophages were
primarily mapped to the V2 region and were found to act by influencing early events of viral infection. By an
assay of viral entry into macrophages, it was shown that viruses with the V2 region from the Ba-L strain of
HIV-1 had >10-fold-higher entry efficiency than viruses with the V2 region derived from the NL4-3 strain. V1
region differences between these groups caused a twofold difference in entry. The known low expression of CD4
on macrophages appeared to be important in this process. In entry assays conducted with HeLa cell lines
expressing various levels of CD4 and CCR5, low levels of CD4 influenced the efficiency of entry and fusion
which were dependent on viral V1 and V2 envelope sequences. In contrast, no effect of V1 or V2 was seen in
HeLa cells expressing high levels of CD4. Thus, the limited expression of CD4 on macrophages or other cell
types could serve as a selective factor for V1 and V2 envelope sequences, and this selection could in turn
influence many aspects of AIDS pathogenesis in vivo.
Infection of cells by human immunodeficiency virus (HIV)
begins with the sequential interaction of the viral envelope
glycoproteins with cellular receptor molecules including CD4
plus one of several chemokine receptors. While more than a
dozen chemokine receptors are known to mediate HIV entry,
the two that are most commonly utilized by HIV isolates are
CXCR4 and CCR5. CXCR4 HIV variants (T-cell tropic) typ-
ically arise late in the disease course and utilize CXCR4 core-
ceptors that are expressed on T cells (17), while CCR5 variants
(macrophage tropic) are typically the transmitted form and
enter cells using CCR5 coreceptors that are expressed on mac-
rophages and T cells (2, 14, 16). The primary determinants
necessary for CCR5 or CXCR4 coreceptor usage have been
previously mapped to the V3 region of the envelope. However,
this domain is not sufficient for high levels of virus infection in
macrophages, as previous experiments have shown that both
nonenvelope and envelope regions other than V3 can alter
macrophage infection (3, 23, 25, 31, 45).
Previously, sequences within the V1 and V2 regions of HIV
envelope have been shown to influence various aspects of mac-
rophage infection. For example, V2 can modulate the influ-
ence of V3 on macrophage tropism and also influences enve-
lope interactions with soluble CD4 (25, 41). In addition, V1
and V2 changes may be required for the efficient production of
virus in macrophages (40, 46). In our previous studies, differ-
ences in V1 and V2 envelope sequences were shown to be
responsible for alterations in efficiency of HIV-1 spread in
monocyte-derived macrophages (43). This effect was specific
for macrophages in that the influence of V1 and V2 regions
was not seen during infection of lymphocytes. Other V1 and
V2 region differences were associated with variations in the
extent of macrophage tropism and the ability to infect cells
expressing low CD4 levels (33) and with the ability to induce
apoptosis in neuronal and glial cells (19). In HIV-1 isolates
adapted to growth in microglia, V1 and V2 region differences
were associated with altered fusogenicity of microglia, al-
though additional substitutions in nonenvelope regions were
required for maximal replication in these cells (39). Addition-
ally, studies of simian immunodeficiency virus–HIV-1 chimeric
virus suggest that specific V2 region alterations are responsible
for in vivo evolution of macrophage tropism from an exclu-
sively T-cell-tropic simian immunodeficiency virus–HIV-1 chi-
meric virus in a rhesus monkey model (21, 22). In summary,
while the V1/V2 region influences macrophage tropism, mi-
croglial tropism, and neurovirulence, the molecular mecha-
nisms behind these effects have not been elucidated.
In the present study, use of new infectious recombinant and
mutant HIV-1 molecular clones demonstrated that the main
sequences responsible for efficient virus spread in macro-
phages were located in the V2 region. The mechanism of this
effect on HIV-1 spread in macrophages appeared to involve an
effect on virus entry into macrophages. In an effort to mimic
* Corresponding author. Mailing address: Rocky Mountain Labora-
tories, 903 S. 4th St., Hamilton, MT 59840. Phone: (406) 375-9354. Fax:
(406) 363-9286. E-mail: bchesebro@niaid.nih.gov.
4828
the low levels of CD4 that are expressed on macrophages (15,
24, 29, 44), viral entry studies were also conducted with cell
lines expressing different levels of the CD4 and CCR5 viral
receptors (35). These experiments provided evidence that low
CD4 levels were a significant barrier to entry of cells by HIV-1
clones with certain V1/V2 sequences. By acting as a selective
factor on viruses during infection of macrophages in brain and
other tissues of AIDS patients, this mechanism may influence
various aspects of pathogenesis and disease progression.
MATERIALS AND METHODS
Construction of recombinant HIV-1 clones. Construction of clone 81A with
the Ba-L strain V1, V2, and V3 regions (designated BBB) in the background of
strain NL4-3 (1) and clone 49-5 with the NL4-3 strain V1 and V2 regions,
followed by Ba-L sequences from StuI to NheI encompassing the C2 and V3
regions (designated NNB) in the same background NL4-3 strain were described
previously (8, 11, 43). To be able to replace V1 and V2 region sequences
independently, additional clones were generated for this study as follows: clone
49-5 was digested with PshAI, and a BamHI linker was inserted to remove this
unique PshAI site. An oligonucleotide polylinker with sites EcoRI-SalI-PshAI-
ClaI-StuI was inserted between the unique EcoRI and StuI sites to generate
clone 46-30. Next, the NL4-3 V1 region plus sequences encoding 18 upstream
residues plus 8 residues of V2 from NL4-3 was inserted between PshAI and ClaI
with a PCR fragment obtained by amplifying pNL4-3-10-17 (8) with PshAI-
containing upper-strand oligonucleotide 1393 (5-TGG GAC CAA AGT CTA
AAG CCA TGT G-3) and ClaI-containing lower-strand oligonucleotide 1395C
(5-TCT TAT CGA TGT GGT GAT ATT GAA AGA GCA-3). This retained
the original amino acid sequence of NL4-3 while creating a unique PshAI site 54
bases upstream from the start of the V1 region. A similar PCR amplification was
done to generate a clone containing V1 sequences from clone JR-CSF (27). An
EcoRI-to-PshAI fragment with upstream pol and env sequences from NL4-3
obtained by PCR amplification with oligonucleotides 5729 (5-AGC CAT AAT
AAG AAT TCT GC-3) and 1405C (5-CTT TAG ACT TTG GTC CCA TAA
A-3) was inserted into these plasmids to replace sequences removed earlier in
clone 46-30. To create clones 21-85 (NBB) and 150-21 (CBB), the above clones
were then digested with ClaI and StuI and used for insertion of the Ba-L V2
region sequences from position 9 to the StuI site located nine residues down-
stream from the end of V2, generated by PCR amplification of 81A with the
ClaI-containing upper-strand oligonucleotide 1406 (5-ACC ACA TCG ATA
AGA GAT AAG GTG CAG A-3) and StuI-containing lower-strand oligonu-
cleotide 6833C (43). V2 sequences from NL4-3 were also amplified with these
same oligonucleotides and inserted to create clone 20-36 (NNB). Clones 20-36
and 49-5 were both designated NNB, but they differed at position 6 of the V2
region (Fig. 1). DNA fragments were generated for various chimeric V2 regions
containing sequences from either NL4-3 or Ba-L by annealing a complex of three
upper-strand and three lower-strand oligonucleotides as described previously
(12), and these V2 sequences were inserted as described above. Clone 146-7
(CCB) was generated by insertion of an EcoRI to a PshAI PCR fragment
obtained by amplifying pNL4-3-10-7 with oligonucleotides 5729 and 1405C into
clone 46-30 to generate clone 67-11. A PCR fragment obtained by amplification
of JR-CSF with PshAI-containing upper-strand oligonucleotide 1393 and StuI-
containing lower-strand oligonucleotide 6833C was then inserted into the PshAI
and StuI sites of 67-11 to create clone 146-7 (CCB).
Virus stocks. Plasmid DNA from molecular clones was used to transfect JC37
CD4- and CCR5-positive (CD4 and CCR5) HeLa cells (35), and these cells
were cocultivated with phytohemagglutinin-stimulated peripheral blood mono-
nuclear cells (PBMC) to produce virus stocks as described previously (8, 9).
Alternatively, JC37 cell supernatants harvested at 48 to 72 h posttransfection
were used to infect fresh JC37 cell cultures which were approximately 25%
confluent. Two days later, when the cells were nearing confluence and the
cultures contained large numbers of multinucleated cells, the medium was
changed. Twenty-four hours later, the supernatant was harvested, centrifuged,
aliquoted, and frozen at 70°C. This was done for 2 consecutive days. Virus
stocks from JC37 cells regularly produced higher titers than those from PBMC.
Stocks from both sources behaved identically in all assays tested. Virus titers
were calculated and expressed as focus-forming units (FFU) or the 50% tissue
culture infectious dose (TCID50). Briefly, HeLa JC37 cultures (35) were infected
and foci were stained by immunohistochemistry (as detailed below). These re-
sults were expressed as the number of FFU per milliliter. In other experiments,
virus infectivity was measured as previously described by endpoint dilution on
PBMC and was expressed as TCID50 values (10). The titers in JC37 and PBMC
assays were in close agreement.
Virus entry experiments. To measure the efficiency of virus entry following
infection of macrophages or the various HeLa-derived cell lines, total cellular
DNA, including reverse-transcribed viral DNA, was isolated and quantified by
real-time PCR analysis. Briefly, before infection, virus stocks were treated with
DNase (Gibco) at a concentration of 200 ng/ml in 10 mM MgCl2 for 30 min at
37°C just prior to use. For negative controls in the entry assay, aliquots of the
DNase-treated virus stocks were heated to 56°C for 30 min prior to infection.
HeLa (CD4 and CCR5) cells, maintained in a rapidly growing state, were
plated at a density of 2.5  104 cells per well of a 48-well tissue culture plate in
0.8 ml of high glucose Dulbecco’s modified Eagle medium (DMEM; Gibco)
supplemented with 10% fetal calf serum. The following day, the medium was
removed, and the cells were treated for 30 min at 37°C with 0.2 ml of DEAE-
dextran at a concentration of 8 g/ml in DMEM without serum. This solution
was then removed, and the cells were infected for 2 to 3 h with 0.1 ml of two serial
10-fold dilutions of virus stock. At the end of this period, 0.8 ml of DMEM with
10% fetal calf serum was added. Eighteen hours later, cells were rinsed with
phosphate-buffered saline (PBS). Total cellular DNA was prepared with the
DNeasy Tissue kit (QIAGEN catalog number 69504). Briefly, each well received
0.2 ml of PBS, 20 l of proteinase K solution, and 0.2 ml of lysis buffer (buffer
AL). The tissue culture tray was sealed with Parafilm, wrapped with Saran Wrap,
and floated in a water bath at 70°C for 30 min. Subsequent DNA purification was
completed according to the manufacturer’s instructions. The DNA was eluted
from the column with a single elution volume of 0.1 ml. The eluted DNA was
used directly for real-time PCR analysis. After isolation, total cell DNA was
stored at 4°C until real-time PCR analysis was conducted.
In an effort to demonstrate that the real-time PCR signal measured from total
cell DNA harvested at 18 h postinfection was an accurate reflection of only the
quantity of virus that entered and not an indicator of initial entry plus additional
rounds of infection, preliminary experiments were conducted at multiple time
points surrounding the 18-h postinfection time point. These preliminary exper-
iments were conducted in the presence and absence of the protease inhibitor,
ritonavir, which limits infection to a single round, since newly generated virus is
not infectious in the absence of protease activity. No difference was noted upon
comparison of the real-time PCR data in the presence and absence of ritonavir;
thus, the 18-h time point was sufficiently early enough in the life cycle of the virus
that only levels of initial infection would be measured (data not shown).
For entry experiments in monocyte-derived macrophages, elutriated human
monocytes (Advance Biotechnologies Incorporated, catalog number 07-210-001)
were plated at a density of 5  105 cells per well of a 48-well tissue culture plate.
The cells were maintained in 0.8 ml of macrophage medium (DMEM, 4 mM
L-glutamine, 20% fetal calf serum, and 10% human AB serum [Advance
Biotechnologies Incorporated, catalog number P2-201-100]). On day 8 after
plating, the medium was removed, and the macrophages were treated for 30 min
FIG. 1. Comparison of envelope amino acid sequences from the V2
regions of four chimeric infectious molecular HIV-1 clones. Recom-
binant clones were generated by the insertion of V1, V2, and V3 from
the macrophage-tropic strain Ba-L in place of the original LAI enve-
lope sequences of the infectious clone pNL4-3-10-17 derived from
NL4-3. The names of each clone are indicated to the left of each
sequence, followed by letters in parentheses that indicate whether the
V1, V2, or V3 regions were derived from NL4-3 (N) or Ba-L (B),
respectively. Amino acid residues are numbered starting from the first
cysteine residue of the V2 hypervariable domain. Dashes indicate
deleted residues. Relative locations of ClaI and StuI restriction endo-
nuclease sites utilized in cloning reactions are indicated. Clone 20-36
(NNB) is identical to clone 21-85 (NBB) in the V2 amino acids up-
stream of the ClaI site, while these clones both differ from clone 49-5
(NNB) at V2 residue 6. Therefore, clones 20-36 and 21-85 were com-
pared to eliminate a role for V2 residue 6 variations.
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at 37°C with 0.2 ml of DEAE-dextran at a concentration of 8 g/ml in DMEM
without serum. This solution was then removed, and the macrophages were
infected for 2 to 3 h with 0.1 ml of the same dilutions of virus stock as were used
for the control JC37 HeLa (CD4 and CCR5) cells. At the end of this period,
0.8 ml of macrophage medium was added. Eighteen hours later, total cellular
DNA was isolated and stored at 4°C until real-time PCR analysis was conducted.
Real-time PCR analysis. Reaction mixtures were (each) 30 l containing 10 l
of total cell DNA as eluted, 15 l of 2 PCR master mix (Applied Biosystems,
catalog number 4304437), 41F primer (5-GGCTAACTAGGGAACCCACTG
C-3) at 350 nM, 118R primer (5-CAACAGACGGGCACACACTACT-3) at
350 nM, and U5 probe (6-carboxyfluorescein-AAGCCTCAATAAAGCTTGCC
TTGAGTGCTC-6-carboxytetramethylrhodamine) at 180 nM. The probe and
primers, specific to the HIV-1 U5 region, were designed with the Applied
Biosystems software Primer Express. The 30-l reaction mixtures were split
between two wells in a 384-well plate to provide duplicate critical threshold
measurements. Neither the presence of DNeasy column elution buffer nor the
presence of uninfected cell DNA altered the critical threshold values (CT) ob-
tained for a plasmid standard. PCR thermal cycling was carried out using the
default settings for the AB 7900HT Sequence Detection system (10-min dena-
turation at 95°C, followed by 40 cycles, each consisting of 15 s of denaturation at
95°C and 1 min of annealing and extension at 60°C). Data shown in Fig. 3 and 4
were calculated by obtaining the CT value (cycle where the PCR amplification
initiated the linear phase) for each sample. CT was calculated for each virus by
subtracting the CT value for entry in JC37 cells from the CT value for entry of the
same sample in macrophages, and the CT values were normalized to entry by
clone 81A by subtracting the 81A value from each to obtain a CT value. The
percent entry for each clone was calculated by the following formula: percent
entry relative to clone 81A  100(2CT). For the results shown in Fig. 5, data
was calculated similarly, except CT represented the CT value for entry in JC24
cells subtracted from the CT value for entry of the same virus stock in the
indicated HeLa cell line. Calculations for the results shown in for Fig. 6 were
similar, except CT was calculated for each virus by subtracting the CT value for
entry in JC37 cells from the CT value from entry of the same virus in the
indicated HeLa cell line, and the percent entry was calculated with the above
equation without 81A normalization.
Immunohistochemical detection of HIV-infected foci. Three days after infec-
tion of the HeLa (CD4 and CCR5) cells as described above, cells were stained
for p24 antigen. The medium was removed, and the cells were fixed with 95%
ethanol for 10 min, then rinsed twice with wash buffer (0.01 M Tris-HCl [pH 7.5],
0.15 M NaCl, 0.002 M EDTA, 1% fetal bovine serum [FBS]). The wash buffer
was aspirated, and 0.15 ml of supernatant from hybridoma 183-H12-5C (AIDS
Research and Reference Reagent Program [ARRRP], catalog number 1513) was
added. After incubation at room temperature for 30 min, the antibody was
aspirated and the cells were washed twice with wash buffer. An aliquot of 0.15 ml
of peroxidase-conjugated goat anti-mouse immunoglobulin (ICN/Cappel catalog
number 55556) at a 1/500 dilution in wash buffer was added. The cells were then
incubated at room temperature for 30 min. After this incubation, the antibody
was aspirated, and the cells were washed twice with wash buffer. Then, 0.3 ml of
peroxidase substrate (0.25 ml of 2 M sodium acetate [pH 5.0], 0.5 ml of 4 mg of
3-amino-9-ethylcarbazole [Sigma catalog number A-5754]/ml in dimethylform-
amide [Sigma catalog number D-4254], and 5 l of 30% H2O2 [Calbiochem
catalog number 386790] to final volume of 10 ml with H2O) was added, and the
cells were incubated for 30 min at room temperature. The substrate was aspi-
rated, the cells were washed with water, and the foci were counted with a Nikon
SMZ-10 microscope. JC37 cells were used in the virus titrations, and the results
were expressed as the number of FFU per milliliter. Alternatively, light micro-
graphs were generated utilizing a Nikon Eclipse TE300 microscope and the
associated Nikon DXM1200 digital camera.
Assay for p24. At 3- to 4-day intervals, one-half of the supernatant was
removed from infected PBMC cultures and from infected macrophage cultures
and frozen at 70°C. The cultures were then fed with growth medium, and
incubation was continued at 37°C until the next time point. The supernatant was
assayed for p24 protein with a p24 capture enzyme-linked immunosorbent assay
developed in this laboratory. Briefly, the anti-p24 monoclonal antibody 183-
H12-5C (ARRRP catalog number 3537) was diluted 1/800 in 0.05 M sodium
carbonate buffer (pH 9.6) or in PBS (pH 7.2), and 0.1 ml was added to each well
of Immulon 2 HB plates (Thermo Labsystems catalog number 3655). The plates
were incubated overnight at 37°C and then washed once with PBS. Plates were
blocked by incubation with 0.25 ml of PBS containing 5% FBS for 1 h at 37°C.
Plates were washed twice with wash buffer (PBS containing 0.2% Tween 20).
Culture supernatants were mixed with 1/10 volume of PBS containing 10%
Triton X-100. Dilutions of supernatants and subsequent antibodies were made in
PBS containing 5% FBS and 0.5% Triton X-100. An aliquot of 0.1 ml of the
diluted culture supernatant was then added to each well, and the trays were
incubated at 37°C overnight. The plates were washed four times with wash buffer,
and 0.1 ml of a 1:1,000 dilution of human anti-HIV antibody (ARRRP catalog
number 192), biotinylated by standard procedures, was added to each well. The
plate was incubated for 1 h at 37°C and washed four times with wash buffer. An
aliquot of 0.1 ml of horseradish peroxidase-conjugated streptavidin (Oncogene
catalog number OR03L) at a 1/2,000 dilution was added to each well, and the
trays were incubated for 30 min at 37°C. The plates were washed six times with
wash buffer, 0.1 ml of peroxidase substrate (10 ml of 0.01 M sodium acetate [pH
5.0], 0.3 ml of 4 mg of tetramethylbenzidine [Calbiochem catalog number
613545]/ml in dimethyl sulfoxide, and 5 l of 30% H2O2) was added, and the
plates were incubated at room temperature until the optical density at 630 nm of
the most concentrated standard (1,000 pg/ml) was 1.2. The reaction was stopped
with 0.05 ml of 2 M H2SO4, and the optical density was read at 450 nm. Values
were compared to a standard curve made with p24 (ARRRP catalog number
382) at concentrations from 25 to 1,000 pg/ml.
RESULTS
Influence of envelope V1 and V2 sequences on infection of
macrophages. Our previous results indicated that sequences in
the V1/V2 region of the HIV-1 envelope gene influence the
ability of the virus to spread after infection of macrophages in
vitro. To determine whether V1 or V2 or both regions were
involved in this effect, recombinant chimeric infectious HIV-1
clones were generated in which the V1, V2, and V3 sequences
from the macrophage-tropic strain Ba-L were inserted in var-
ious combinations in place of the original LAI envelope se-
quences in the infectious clone pNL4-3-10-17 derived from
NL4-3. In addition to the previously described clones 81A
(BBB) and 49-5 (NNB) (43), we generated clone 21-85 con-
taining the V1 region of NL4-3 and the V2 and V3 regions of
Ba-L (NBB) for the present study. We also generated a second
NNB clone, 20-36, containing the V1 and V2 sequences of
NL4-3 plus the V3 of Ba-L to eliminate a variability in residue
6 of V2 upstream of the ClaI site in clone 49-5 (Fig. 1).
Cultures of PBMC and macrophages were infected with
virus generated from the group of chimeric HIV-1 clones that
contained V1 and V2 regions from NL4-3 at high and low
inputs of virus per culture, and replication was measured by
p24 capture enzyme-linked immunosorbent assay (Fig. 2).
Each chimeric virus grew well in the PBMC cultures, reaching
high p24 levels after 10 days. After the infection of macro-
phages with high virus input, BBB and NBB clones grew rap-
idly. In contrast, NNB clones grew slowly. NNB clones reached
a plateau of p24 in supernatant which was 100-fold lower than
that attained by the other clones (Fig. 2). Similar results were
seen for the chimeric viruses after infection with the lower
input. A minor delay in BBB replication at the lower input was
observed in this single experiment; however, BBB and NBB
clones both spread effectively to high levels by day 20 in this
and three other independent experiments. Thus, the V2 region
of Ba-L appeared to be required for high-level infection and
spread in macrophage cultures. On the other hand, the V1
region exerted only very limited effects when combined with
V2. These effects were specific for macrophages, as there was
no difference seen in the infection of PBMC by these same
viruses.
Similar experiments were conducted with chimeric clones,
CBB and CCB, which contained V1 and V2 regions from
JR-CSF (27) instead of NL4-3 (Fig. 2). While CCB and CBB
grew to similar levels in PBMC and in macrophages, CCB grew
slowly compared with CBB and BBB. Hence, similar macro-
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phage-specific effects were observed in both NL4-3 and JR-
CSF chimeras. We were unable to test the effect of the Ba-L
V1 without the Ba-L V2 because multiple BNB and BCB
clones were not viable.
NNB clones produce infectious virus in macrophage cul-
tures. Since the viral stocks used in the above experiments and
our previous studies were made with PBMC or JC37 HeLa
(CD4 and CCR5) cultures, one possible explanation for the
lack of spread of NNB viruses in macrophage cultures might be
a defect in virus output in macrophages, leading to lack of
production of infectious virus after the initial infection. To test
this possibility, supernatants from infected macrophages were
tested for infectivity. In these experiments, NNB virus was
detectable at low levels in the supernatants of the infected
macrophage cultures (Table 1). Using supernatant fluids from
macrophage cultures infected by BBB clones, higher levels of
infectious virus were detectable. Thus, although NNB virus
titers produced by macrophage cultures were lower than those
of BBB viruses, this difference appeared to reflect the differ-
ence in the percent of macrophages infected by these clones, as
there did not appear to be an overall inability of macrophages
to release infectious NNB virus (Table 1).
NNB clones have reduced entry in macrophages. Another
explanation of the lower level of infection of macrophage cul-
tures by NNB viruses might be a defect in viral entry. To
examine this possibility, macrophage and JC37 HeLa (CD4
FIG. 2. Influence of HIV-1 V1 and V2 envelope sequences on kinetics of p24 production following infection of PBMC (left) and macrophage
(right) cultures with either high or low inputs of virus generated from clone 81A (BBB) (F), 21-85 (NBB) (Œ), 49-5 (NNB) (■ ), CBB (‚), or CCB
(). High-input experiments were done using a 1,000 to 2,500 PBMC TCID50 for infection, and low-input experiments were conducted using a
100 to 250 PBMC TCID50. The V2 region of Ba-L was required for high-level infection of macrophages but not PBMC. These data are from a
single experiment that was representative of results obtained in four independent experiments.
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and CCR5) cultures were analyzed in a viral entry assay with
various HIV-1 clones. JC37 cells were utilized as the permis-
sive positive control cell line in these entry studies to alleviate
the variability associated with individual PBMC preparations.
Viral entry was measured by quantitative real-time PCR anal-
ysis of reverse-transcribed viral DNA from cells 18 h after virus
infection. In these studies, NNB clones showed a consistent
10-fold decrease in the entry of macrophages compared to
BBB clones, whereas NBB clones showed only a 2-fold de-
crease (Fig. 3). This result was observed at two input levels
differing by 10 fold, and appeared to explain, in part, the lower
levels of infection and spread by NNB viruses in macrophages
seen above.
To determine which amino acid residues in V2 might ac-
count for these differences in entry, a series of mutant V2
clones were generated and tested. A total of 6 residues out of
the 40 in V2 differed in the NBB versus NNB clones used for
this study (Fig. 4). In the viral entry studies, no single amino
acid position appeared to completely control entry; however,
three mutant clones (BN4, BN5, and BN1) entered cells sim-
ilarly to the NBB parental clone (Fig. 4). The only common
mutant residue in all three of these clones was glutamic acid
(E) at position 22, but this change alone in mutant BN8 was
not sufficient to give a high entry level. These data indicated
that multiple residues in V2 are required to produce the ob-
served changes in viral entry associated with the V2 region of
the Ba-L clone.
Entry of NNB clones is influenced by target cell surface CD4
concentration. While PBMC have been shown to express 105
CD4 molecules per cell (28), macrophages express CD4 at
relatively low or undetectable levels (15, 20, 24, 29, 44). To
examine whether low cell surface concentrations of CD4 on
macrophages could be responsible for the distinct entry phe-
notypes of the clones described above, we utilized two panels
of HeLa cell lines that expressed differing levels of CD4 (35).
The JC series expressed 4  105 CD4 molecules per cell,
which is similar to PBMC, while the RC series expressed 104
CD4 molecules per cell, which is similar to levels previously
estimated on differentiated macrophages (20, 24). In addition
to the two distinct levels of cell surface CD4, multiple JC and
RC subclones expressed various, defined levels of CCR5 (35).
When cells with high CD4 levels were tested (JC37), viral
entry was similar for BBB, NBB, and NNB clones; thus, the
differences in the V1 and V2 regions had no effect (Fig. 5). In
contrast, when CD4 levels were 10- to 40-fold lower (cell lines
RC49 and RC30), the pattern of entry was similar to that
observed in macrophages, as BBB and NBB viruses entered at
a high level, whereas NNB viruses entered poorly (Fig. 5).
These results were similar whether CCR5 cell surface expres-
sion was high (RC49) or low (RC30). Since differentiated mac-
rophages have low CD4 levels, these results suggested that the
reduced macrophage entry by HIV-1 clones containing V2
sequences from NL4-3 was associated with the relatively low
levels of CD4 expressed on these cells.
HIV-1 entry and spread is modulated by cell surface recep-
tor-coreceptor concentrations and V1/V2 loop sequences. To
study the role of various CCR5 concentrations in the context of
both high and low CD4 expression, several additional HeLa
cell lines were analyzed for viral entry by the three types of
HIV-1 clones, BBB, NBB, and NNB. These results together
with those shown in Fig. 5 are presented as a function of CCR5
concentration in Fig. 6. In the JC series of cell lines where CD4
expression was high, all three types of viruses were capable of
efficient entry over a wide range of CCR5 expression levels.
Only in JC10 cells, which expressed the lowest CCR5 levels,
was a significant decrease in entry observed (Fig. 6). No entry
was seen in the original CCR5-negative cell clone (HI-J), con-
firming that CCR5 expression was required for entry by these
viruses. The slight decrease in entry using JC48 and JC24 cells
appeared to be due to the loss of some of these cells from the
monolayer during extensive fusion at the time of infection. In
contrast to the results with JC lines, CCR5 expression level was
critical in the RC lines, which expressed a 40-fold-lower CD4
level, and entry was reduced concurrently with CCR5 expres-
sion. Again, no entry was seen when CCR5 was not present
(clone HI-R). In the RC cell lines, BBB virus entered at a level
slightly better than NBB, and NBB in turn entered better than
NNB (Fig. 6). Together these data suggest that limiting quan-
tities of cell surface CD4 or CCR5 had dramatic effects on the
entry phase of viral infection by certain HIV-1 clones, depend-
ing mostly on their V2 envelope sequences; however, V1 also
FIG. 3. Comparison of the relative abilities of chimeric HIV-1
clones to enter macrophages. The values shown are relative percent
entry, normalized to clone 81A (BBB). Calculation of relative percent
entry was described in Materials and Methods. Error bars represent
the standard errors of the mean. The virus input represents FFU as
determined by titers of the virus on JC37 HeLa (CD4 and CCR5)
cells. The real-time PCR data for each point was collected in five
independent experiments in which each data point was assayed in
duplicate for two separate virus dilutions.
TABLE 1. Detection of infectivity in supernatant of
HIV-1-infected macrophagesa
Virus % Infected macrophages PBMC Titer
81A (BBB) 50 9  102
81A (BBB) 25 2  102
49-5 (NNB) 5 3  101
49-5 (NNB) 2 1  101
a Macrophage cultures were infected 7 days previously with 2  103 TCID50s
of HIV-1 from infected PBMC; medium was changed on days 1 and 4, and
supernatant fluid was collected on day 7 for analysis of infectious virus by
endpoint titration on PBMC. Titers are TCID50 values per 0.1 ml. The percent
infected cells was determined by indirect immunostaining of cells with anti-p24
monoclonal antibody, 183-H12-5C, as described in Materials and Methods.
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played a detectable role in combination with V2, as indicated
in small differences observed between BBB and NBB clones in
these experiments.
Influence of CD4 and CCR5 concentrations on viral fuso-
genicity and spread. In our previous studies, we noted that
BBB clones, which spread extensively in macrophages, also
induced a high level of cell fusion during infection, in contrast
to NNB clones which spread poorly and failed to fuse macro-
phages (43). Therefore, we were also interested in studying the
effects that cell surface receptor concentrations and viral V1
and V2 sequences might have on fusogenicity and spread of
virus in the JC and RC HeLa cell lines. Following infection of
these lines, virus was allowed to enter and spread throughout
the cultures for a period of 3 days, at which time the cultures
were fixed and stained for viral p24 antigen.
When CD4 concentrations were high (JC cell lines) and
CCR5 levels were constant, BBB, NBB, and NNB viral clones
were similar in levels of both entry and fusion, but the extent
of cell fusion induced by these viruses was greatly influenced by
CCR5 concentrations (Fig. 7). On JC10 cells, which have the
lowest CCR5 levels, virus antigen-positive foci were found in
small clusters of two to five cells with minimal fusion, whereas
on JC37, antigen-positive foci were multinucleated giant cells
with 10 to 20 nuclei each; on JC24 cells, with the highest CCR5
levels, viral foci were even larger than those seen with JC37
cells (Fig. 7).
Results were quite different on cells expressing lower CD4
levels. For example, in RC30 cells expressing low CD4 and low
CCR5 levels, small foci with minimal fusion and spread were
seen with each of the viral clones (Fig. 7). However, in RC49
cells (low CD4 and high CCR5 levels), extensive fusion with
large multinucleated giant cells was induced by the BBB virus,
smaller foci with fusion were induced by the NBB virus, and
tiny foci with minimal fusion were induced by the NNB virus
(Fig. 7). Thus, in both entry and fusion-spread assays, the
RC49 cell line appeared to act similarly to macrophages in-
fected by these same clones.
DISCUSSION
In our previous studies, the V1 and V2 hypervariable do-
mains of the HIV-1 envelope surface glycoprotein influenced
the replication efficiency of macrophage-tropic HIV-1 by af-
fecting virus spread in macrophage cultures but not in PBMC
cultures (43). In the present experiments, V2 residues had the
most influence on spread and replication in macrophages,
while the V1 residues exerted a lesser effect. Measurement of
NNB virus production by macrophages indicated that the in-
fectious virus was produced in a quantity proportional to the
number of infected cells. Therefore, lack of NNB virus pro-
duction by macrophages did not appear to explain the low
levels of replication and spread seen in macrophages infected
with NNB clones. In contrast, infectious entry into macro-
phages was 5- to 10-fold higher for NBB and BBB viruses,
respectively, than for NNB viruses (Fig. 3). This effect was
macrophage specific and was not seen in JC37 HeLa (CD4
and CCR5) cells (Fig. 5). Therefore, this defect in virus entry
FIG. 4. Macrophage entry by parental and mutant HIV-1 clones differing in V2 residues as shown. Boxed residues are from the Ba-L clone and
unboxed residues are from the NL4-3 clone. Values shown are percent entry relative to the 81A clone (100%). The real-time PCR data for each
point was collected in three independent experiments in which each data point was assayed in duplicate on two separate virus dilutions.
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appeared to correlate well with the poor replication and spread
of NNB viruses in macrophages.
While all HIV-1 clones tested were able to enter HeLa-CD4
and CCR5 cells expressing high levels of CD4, our experiments
conducted in HeLa cells expressing lower cell surface CD4
concentrations provide a possible explanation for how viruses
containing NL4-3 V1 and V2 hypervariable regions distinguish
macrophages from PBMC. These HeLa cells were not effi-
ciently entered by viruses containing NL4-3 V1 and V2 hyper-
variable regions (NNB) (Fig. 5 and 6). Since macrophages have
been shown to express low levels of cell surface CD4 concen-
trations (15, 24, 29, 44), a similar effect is likely to occur in
macrophages. Therefore, we propose that NNB viruses distin-
guish macrophages from PBMC based upon cell surface CD4
concentrations. While cells that express CD4 above a threshold
level (JC lines and PBMC) can be efficiently entered by viruses
with NL4-3 V1 and V2 regions, cells that express CD4 below
this threshold (RC lines and macrophage) are not. Our data
using clones expressing V1 and V2 sequences from JR-CSF
(Fig. 2) suggest that this effect might be a general phenome-
non. This conclusion is supported by numerous previous re-
ports describing HIV clones or isolates with differing abilities
to infect cells expressing low CD4 levels. In some cases, this
ability has correlated with the distinction between macrophage-
tropic and non-macrophage-tropic viruses (4, 33), but in other
cases this ability has been associated with an enhanced ability
to cause apoptosis in neuronal cultures (19) or increased rep-
lication capacity in microglia (39). The results in the latter
study differ from our data in that the main effect of viral
envelope appeared to map to the V1 region, rather than to V2.
In contrast, one previous study demonstrated that the reduced
macrophage entry observed for a group of R5 primary isolates
was not moderated by increased expression of CD4 (18), so
CD4 level may not be the only macrophage attribute capable of
influencing efficiency of HIV infection.
In an effort to map more precisely V2 residues responsible
for the effects observed on virus entry and spread in macro-
phage cultures, we generated additional infectious recombi-
nant HIV-1 clones that contained NL4-3–Ba-L chimeric V2
sequences. All viruses that efficiently entered macrophages had
a negatively charged glutamic acid residue from the Ba-L clone
at V2 position 22 instead of a positively charged lysine residue
from the NL4-3 clone (Fig. 4). However, clone BN8, which had
only this substitution had a low entry level, and one clone
(BN2), lacking glutamic acid at position 22, had intermediate
levels of entry. These results indicate that this single amino
acid substitution is neither necessary nor sufficient for a high
entry level, and other structural features must also be impor-
tant. For example, V2 contains three N-linked glycosylation
sites that modulate the interaction of HIV-1 envelope with
CD4 and CCR5 to specifically influence macrophage infection
but not PBMC infection (30). In our clones, the glycosylation
site at residue 32 in the V2 of Ba-L was relocated to residue 30
in the V2 of NL4-3. Perhaps these differences in glycosylation
sites in the V2 region also influence viral entry level. Since no
single amino acid residue or distinct region of V2 appeared to
completely control entry, it is likely that overall V2 conforma-
tion is an important factor in the effects observed.
While the HeLa cell entry data suggested a definitive role
for CD4 concentration in modulation of macrophage entry, the
precise mechanism of V1 and V2 involvement is not known.
Since no V1 or V2 residues have been shown to directly inter-
act with CD4, it is unlikely that a direct V1/V2–CD4 interac-
tion could account for the observed CD4-dependent effects of
V1/V2. On the other hand, two distinct mechanistic possibili-
ties could explain how CD4 concentrations could differentially
modulate entry of viruses containing different V1/V2 loops.
The conformation of envelopes containing certain V1 and V2
residues and/or glycosylation patterns could indirectly influ-
ence CD4 binding by other regions of envelope. Alternatively,
when target cell surface CD4 is limiting, envelope conforma-
tional changes that are necessary for productive interactions
with CCR5 might be more efficiently attained when certain V1
FIG. 5. Comparison of the relative abilities of different virus clones
to enter HeLa cells expressing high (JC37) or low (RC49 and RC30)
levels of cell surface CD4. HeLa cell cultures were infected with
recombinant virus clones. The virus clone names are indicated on the
left. The bars correspond to the percent relative entry normalized to
81A (BBB) entry within the same cell line. Error bars represent the
standard errors of the mean. The real-time PCR data for each point
was collected in four independent experiments in which each data
point was assayed in duplicate.
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FIG. 6. Virus entry into HeLa cells as a function of receptor and coreceptor concentrations. Three chimeric viruses (81A [BBB], 21-85 [NBB],
and 20-36 [NNB]) were used to infect HeLa cultures expressing various levels of surface CD4 and CCR5. Solid bars indicate percent relative entry
into RC lines (low CD4) while hatched bars indicate entry into JC lines (high CD4). Percent relative entry was calculated utilizing real-time PCR
analysis of reverse-transcribed HIV DNA contained within the infected HeLa cells. Levels of entry are normalized to levels of entry for each clone
in JC37. The numerical designation of each cloned cell line as well as the relative levels of CD4 and CCR5 expressed on the surface of each line
are indicated to the left of the histograms. Error bars represent the standard errors of the mean. No entry was seen in HI-J and HI-R HeLa-CD4
lines, which did not express CCR5. The data for each point was collected in four independent experiments in which each data point was assayed
in duplicate.
FIG. 7. Immunohistochemical detection of HIV-1-infected foci in HeLa cultures. HeLa cell cultures were infected with a chimeric virus and
on day 3 postinfection were fixed and stained for p24 by an indirect immunoperoxidase technique. The HeLa cell line utilized in each focus assay
along with approximations of the relative concentrations of CD4 and CCR5 expressed on the surface of each line are indicated to the left of each
row of micrographs. The chimeric virus clone used for infection is indicated above each column of micrographs. No foci were seen in HI-J and
HI-R HeLa-CD4 lines which did not express CCR5 (data not shown).
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and V2 sequences and/or glycosylation patterns are present. In
either case, viruses containing Ba-L V2 sequences might re-
quire fewer CD4 interactions for entry than do NL4-3 V2
viruses.
The current model of HIV entry involves two sequential
conformational changes in gp120 prior to activating the actual
fusion machinery in gp41 (for reviews, see references 5 and
34). The first conformational shift occurs as a consequence of
the interaction of CD4 with envelope and results in the cre-
ation, stabilization, or exposure of a coreceptor (i.e., CCR5)
binding site on gp120. Once the envelope binds to the core-
ceptor, the resulting conformational change induces activation
of the fusion domains in gp41 that ultimately mediate fusion
and/or entry. One role of V1/V2 in certain HIV isolates may be
to limit the exposure of certain envelope regions involved in
coreceptor binding until sufficient CD4-envelope interactions
have occurred as a way of hiding the coreceptor binding site
from antibody binding (4, 7, 26, 32, 38, 42, 47, 48). In this
model, part of the envelope coreceptor binding site is occluded
by a V1/V2 arm that is displaced upon CD4-envelope interac-
tion exposing the coreceptor binding site.
In agreement with the above hypothesis, our entry and fu-
sion spread data (Fig. 6 and 7) suggest that certain V2 region
sequences (e.g., NL4-3) can impede HIV-1 entry into cells
expressing limited surface CD4 concentrations. When the
NL4-3 V2 loop was present (NNB viruses) and CD4 concen-
trations were low, entry and fusion spread were severely di-
minished. However, if CD4 expression was increased, this
block was removed, entry was rescued, and fusogenicity be-
came a direct function of CCR5 concentration. On the other
hand, if the Ba-L V2 loop was present (BBB and NBB viruses),
both entry and fusogenicity were still dependent on CCR5
concentrations, but no difference was seen in the two CD4
concentrations tested. Thus, the entry block imparted by
NL4-3 V2 sequences could be removed either by increasing
target cell surface CD4 concentrations or by substitution of
nonblocking V2 sequences (e.g., Ba-L). While our work does
not describe the precise molecular interactions involved in
HIV entry, these studies are in agreement with the hypothesis
of Sodroski and colleagues suggesting that certain V1 and V2
loops (e.g., NL4-3 V1/V2) might act to block CCR5 access to
its envelope binding site until CD4 binds (32, 42, 48). It is
possible that certain V1/V2 sequences (e.g., Ba-L V1/V2)
could impart increased structural flexibility to the V1/V2 loop,
resulting in a decrease in the energy barrier required for the
conformational rearrangements necessary for exposure of the
CCR5 binding site. Hence, in the case of Ba-L V1/V2 viruses,
fewer CD4-envelope interactions would be necessary for entry
compared with the more structurally constrained V1/V2 of
NL4-3 viruses.
Since macrophages and microglia have been shown to ex-
press limited cell surface CD4, the above findings may have
implications for cell tropism and selection of viruses in tissues
such as lung and brain, where macrophages or microglia are
numerous. In such tissues, one would predict selection of HIV
clones with the V1 and V2 sequences associated with efficient
and rapid spread in macrophages. In fact, this result was ob-
served in our previous study of HIV-1 envelope sequences
isolated directly from the brains of infected individuals (36).
Similar findings have been reported by other groups (19, 33).
Possibly these envelope sequences not only facilitate increased
replicative capacity for microglia but also mediate additional
pathogenic potential for brain tissue, leading to the syndrome
of HIV-associated dementia or other central nervous system
manifestations of HIV infection (19, 33). Furthermore, the
selective pressures present under conditions of limiting CD4
might eventually favor CD4-independent viruses, as has been
suggested in both studies conducted with HIV and simian
immunodeficiency virus (6, 37).
At early times in the course of infection, macrophage-tropic
viruses are usually present. In one study, macrophage-tropic
viruses isolated immediately after seroconversion had a slow-
replication phenotype, whereas at later time points more rap-
idly replicating macrophage-tropic viruses were isolated (13).
While the authors demonstrated that both early and late iso-
lates could infect macrophages, the efficiency of entry was not
directly assayed. Possibly the slow-replicating strains found
shortly after transmission are similar to the NNB viruses stud-
ied here. However, it remains unclear what advantage these
slow-spreading clones might have in the complex set of events
that occur during transmission to a new host. In any case, these
viruses would be likely to be important targets for future vac-
cine development.
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